On October 20, 2025, Adagio Medical Holdings, Inc. announced it had closed a private placement, raising $19 million in upfront proceeds. The placement was led by existing investors and new healthcare‑dedicated institutional investors, underscoring continued confidence in the company’s technology.
The private placement, previously announced on October 15, 2025, involved 9,792,506 shares of common stock and 18,038,829 warrants issued at $1.9403 per share. The $19 million upfront proceeds are part of a $50 million private placement, with the remaining potential proceeds contingent on warrant exercise.
The capital infusion addresses the company’s liquidity concerns and supports ongoing clinical development of its vCLAS Cryoablation System, positioning Adagio to advance its purpose‑built technology for ventricular tachycardia.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.